Core Viewpoint - The company Baiyunshan announced that its subsidiary Guangzhou Pharmaceutical intends to acquire 100% equity of Zhejiang Provincial Pharmaceutical Industry Co., Ltd. from Zhejiang Haizheng Pharmaceutical Co., Ltd. through a public transfer, with a transaction price of 500 million yuan [1] Group 1 - The acquisition involves a total equity transfer of Zhejiang Provincial Pharmaceutical Industry Co., Ltd. [1] - The transaction price is set at 500 million yuan [1] - The deal is subject to review by China's antitrust regulatory authority, indicating potential uncertainties [1]

白云山 2025 年第三次临时股东会 广州白云山医药集团股份有限公司 2025 年第三次临时股东会会议资料 2025 年 12 月 30 日 第 1 页 共 12 页 白云山 2025 年第三次临时股东会 目 录 | 一、会议须知……………………………………………………3 | | --- | | 二、会议议程……………………………………………………5 | | 三、会议议案……………………………………………………6 | 第 2 页 共 12 页 白云山 2025 年第三次临时股东会 广州白云山医药集团股份有限公司 2025 年第三次临时股东会会议须知 为了维护广州白云山医药集团股份有限公司（以下简称"本公司"或"公 司"）全体股东的合法权益，确保本公司 2025 年第三次临时股东会（以下简 称"临时股东会"或"本次临时股东会"）正常秩序和议事效率，保证临时股 东会的顺利进行，依据有关法律法规、《广州白云山医药集团股份有限公司 章程》（以下简称"《公司章程》"）及《广州白云山医药集团股份有限公 司股东会议事规则》的有关规定，特制订本须知。 一、本次临时股东会由董事会依法负责筹备、召集及召开各项工作。 二、股东及股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司2025年第三次臨時股東會會議資料之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年12月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 白云山 2025 年第三次临时股东会 广州白云山医药集团股份有限公司 2025 年第三次临时股东会会议资料 2025 年 12 月 30 日 第 1 页 共 12 页 白云山 2025 年第三次临时股东会 目 录 三、股东及股东代表参加本次临时股东会应遵守本次会议议事规则，共 同维护会议秩序，依法享有发 ...

Group 1 - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area Artificial Intelligence and Robotics Industry Conference was held from December 12 to 14, showcasing the latest achievements in the integration of AI and manufacturing [1] - The conference highlighted the construction achievements of the "National Artificial Intelligence Pilot Base," which is the only national-level pilot platform focusing on mobile terminals, co-built by Shenzhen and Dongguan, and constructed by China Unicom [1] - The base aims to enhance "terminal innovation" and "manufacturing efficiency" by establishing five foundational capabilities: computing power, data, models, applications, and security [1] Group 2 - Guangdong Unicom, in collaboration with various organizations, launched the "Guangdong Artificial Intelligence + Manufacturing Industry Alliance" to tackle common technical challenges and promote resource collaboration and achievement transformation [2] - The alliance includes partnerships with major companies such as Huawei, TCL, Midea, and others to accelerate the transformation of technological achievements into industrial practices [2] - Two platforms were officially launched: the "Yuanjing·Wanwuh Industrial Intelligence Platform" and the "Ge Wu·Embodied Intelligent Robot Collaborative Platform," aimed at empowering the entire production process with intelligent capabilities [1][2]

Group 1 - The 2025 China Innovation and Entrepreneurship Achievement Trading Conference and the China Overseas Talent Exchange Conference opened in Guangzhou, marking the first comprehensive market-oriented approach for both events [1] - The joint conference aims to accelerate the integration of talent, technology, and industry, serving as a significant practice for Guangzhou to support national strategies and align with innovation trends [1] Group 2 - The 2025 Guangzhou Unicorn Innovation Enterprise List was released, featuring 210 companies, including 26 "unicorn" companies, 105 "future unicorns," and 79 "seed unicorns" [2] - The number of "future unicorn" companies increased by 4% compared to last year, while "seed unicorn" companies grew by 13% [2] - High-tech enterprises make up 77% of the listed companies, with 63% concentrated in information technology, biomedicine, artificial intelligence, and advanced manufacturing [2] Group 3 - The list showcases a well-structured ecosystem with strong international competitiveness, as leading "unicorns" average 496 intellectual property rights and 107 invention patents [3] - Notable companies include GAC Aion, Yuanchip Semiconductor, and Zhongke Aerospace, all valued over 10 billion RMB, demonstrating large scale, mature business models, and high globalization [3] - "Future unicorns" exhibit robust technical capabilities, with an average of 125 intellectual property rights and 30 invention patents, focusing on niche areas such as targeted cancer drug development and AI robotics [3] Group 4 - "Seed unicorn" companies show strong innovation vitality, averaging 34 intellectual property rights, and include leaders in quantum technology and high-end semiconductor packaging [4] - The conference also launched the "Most Influential Emerging Overseas Returnee Entrepreneur" list and the Greater Bay Area Future Unicorn list [4] - The Guangzhou State-owned Assets and Enterprises Think Tank Alliance was established, and the finals of the 2025 Overseas Talent Entrepreneurship Competition were initiated [4] Group 5 - The conference has facilitated project conversion worth over 998 billion RMB in the past decade, aiming to bridge the gap in project implementation [5] - Innovative projects showcased include a multi-sensory system for tinnitus treatment and a preservation technology for lychee, indicating significant market potential [5] - The Guangdong Provincial Hospital of Traditional Chinese Medicine presented various health products developed by the hospital [5] Group 6 - The Overseas Talent Exchange Conference has attracted over 50,000 overseas talents, facilitating their return to domestic development [6] - An international talent recruitment fair was held, featuring numerous tech companies offering attractive positions, with a high percentage of candidates holding master's degrees or higher [6] - The recruitment fair provided a comprehensive service experience for job seekers, including resume diagnostics and career development guidance [6]

证券代码：600332 证券简称：白云山 公告编号：2025-086 一、《药品生产许可证》基本情况 企业名称：广州白云山星珠药业有限公司 许可证编号：粤20160117 分类码：Ay 注册地址：广州市从化明珠工业园创业大道南4号 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广东省药品监督管理局发布了《广东省药品监督管理局关于注销〈药品生产许可证〉的通告 （2025年第102号）》，广州白云山医药集团股份有限公司（以下简称"本公司"）子公司广州白云山星 珠药业有限公司（以下简称"星珠药业"）《药品生产许可证》已注销，本次注销的原因是星珠药业进行 生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期届满后不再申请重新发证。现 将相关情况公告如下： 发证机关：广东省药品监督管理局 有效期至：2025年9月9日 生产地址和生产范围：广州市从化明珠工业园创业大道南4号， 特此公告。 广州白云山医药集团股份有限公司董事会 2025年12月15日 ...

证券日报网讯 12月15日，白云山在互动平台回答投资者提问时表示，公司应收账款主要集中在医药流 通业务，公司通过优化客户信用管理、强化回款机制和资产证券化等工具控制风险及提升资金周转效 率。 （文章来源：证券日报） ...

证券日报网讯 12月15日晚间，白云山发布公告称，近日，广东省药品监督管理局发布了《广东省药品 监督管理局关于注销的通告（2025 年第 102 号）》，广州白云山医药集团股份有限公司（以下简称"本 公司"）子公司广州白云山星珠药业有限公司（以下简称"星珠药业"）《药品生产许可证》已注销，本 次注销的原因是星珠药业进行生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期 届满后不再申请重新发证。 （编辑 楚丽君） ...

香港联交所最新资料显示，12月9日，小摩减持白云山(00874)11.2万股，每股作价18.581港元，总金额 约为208.11万港元。减持后最新持股数目约为1969.23万股，最新持股比例为8.95%。 ...

智通财经APP讯，白云山(00874)发布公告，近日，广东省药品监督管理局发布了《广东省药品监督管理 局关于注销<药品生产许可证>的通告(2025年第102号)》，广州白云山医药集团股份有限公司(以下简 称"本公司")子公司广州白云山星珠药业有限公司(以下简称"星珠药业")《药品生产许可证》已注销，本 次注销的原因是星珠药业进行生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期 届满后不再申请重新发证。 星珠药业进行生产经营业务调整，将主要业务集中在中药前处理提取业务上，在生产范围为中药饮片的 《药品生产许可证》有效期届满后，不再申请重新发证，将该《药品生产许可证》注销。星珠药业2024 年中药饮片业务没有产生营业收入。 ...